Subject Index

A

abortion, spontaneous 20
acute viral myocarditis 299
adenine nucleotid translocator 264
adenovirus type 2 212
adhesion molecules 297
adsorption 211
adult polymyositis 20
agammaglobulinemia 25, 65
alignments 173
amyotrophic lateral sclerosis 19
animal experiments 46, 47
anti-idiotypic antibodies 274
antibody
– determination 72
– escape mutant 236
antigen detection 70
antiviral therapy 74
antivirals 251
aseptic meningitis 58
atherogenic diet 82
attachment 211
attenuation 250
autoantibodies 260, 284, 288
autoimmunity 289
azathioprine 288

B

2B coding region 237
basetriples 178
Bornholm disease 67
branched chain keto acid dehydrogenase 264
bronchopneumia 66

C

canyon hypothesis 193, 210
capsid 155, 156
capsid proteins 98, 246
– VP1 (1D) 98, 104
– VP2 (1B) 98, 104, 105
– VP3 (1C) 98, 105
– VP4 (1A) 98, 103
cardiac myosin 264
cardiomyopathy (see also myocarditis) 262
– dilated 228, 283, 299
cardiopathologic antibodies 262
cardiovirulence 45, 46, 234
cardioviruses 248, 249
carditis 17
CD55 160
cDNA, infectious 229, 241
children
– aseptic meningitis 62–65
– encephalitis 62–65
– disease in 53–74
– illness duration 63
– prognosis 63
– systemic illness, risk for severe 62
chimeric viruses 229, 234, 242, 251
chronic fatigue syndrome 19
chronic myopathies 19

compensatory base pair mutation 173, 186
complement fixation 72
consensus structure 186
coxsackievirus virulence, genetics 227–251
coxsackieviruses, taxonomy 1–3
coxsackieviruses of group A 2, 66, 69
coxsackieviruses of group B (CVB) 2
– avirulent 250
– – phenotypes 245, 246
– binding site for specific cellular receptors 4
– cellular receptors 209
– CVB2 99, 116, 122, 245
– – serotypes 117
– CVB3 98, 118, 122, 123, 182–186, 191f., 261
– – amino acid sequence 196
– – atomic model 196
– – cardiovirulence 182, 234
– – 5' NTR 185
– – nucleotide 234 182–184
– – – mutations 185
– – replication efficiency 182
– – serotypes 117
– – structure 191–206
– – – capsid proteins 198–202
– – surface-exposed residues 128
– – surface topology 203
– – threedimensional structure 244
– CVB4 131–150, 240
– CVB5 69, 153–165
– – antigenically related to SVDV 154f.
– – capsidstructures 160
– – first isolation 153
– – host range 155
– – higher order structures of nontranslated region RNA 169–187
– – polypeptide patterns 162
– – variation 162
– epidemiology 13f.
– genetic divergence 97–150
– genome length 98
– human diseases 4–6
– induced disease, role of humoral response 259–274
– infections 70
– – diagnosis 70
– – isolation 70
– meningitis 62
– pathogenicity for newborn outbred mice 3
– properties 3
– RNA genome 3, 4
– serotype 98, 245
– strain 98
– strains, naturally occuring 250
cyclosporin A 288
cytokines 267, 286
cytosine-rich pyrimidine tract 102

D

Dallas histological criteria 36
demyelination 249
dermatomyositis 68
– juvenile 20
diabetes mellitus 18
– insulin-dependent 238, 260
– viral-induced-insulin-dependent (IDDM) 5
diabetogenic phenotype 241
dilated cardiopathy 299
N,N'-diphenyl-p-phenylenediamin (DPPD) 88
disease in children 53–74
dot matrix histogram 177
double helix 172
DPPD (see N,N'-diphenyl-p-phenylenediamin)
drug binding pocket 193
dynamic programming algorithm 175

E
E2 99
echovirus 6 215
echovirus 7, cellular receptor for 215
eclipse 212
encephalitis 64
– focal 64
– global 64
enteric illness 68
enterovirus 3
– infections 23
– monoclonal antibodies 71
epidemiology 13–26
– endemic incidence 14
– epidemic incidence 14
epitopes 22
– shared with CVB3 269
etiologic association 16
EV 9 viruses 163
exanthems 69
exercise 90

F
febrile seizures 63
fetal
– demise 19, 20
– infection 56
– loss 56
fish oil 88
free-energy data 173
functional domains 186

G
GAD (see glutamic acid decarboxylase)
gastrointestinal illnesses 68, 69
gene regulation 177
genetic
– algorithm 175
– variants 23
genotype 15, 86
glutamic acid decarboxylase (GAD) 266

H
hairpin algorithms 174
hand washing 60
hand-foot-and-mouth disease 69
heart disease (see also cardio-myopathie) 31–48
– inflammatory 19
– mechanisms of disease 46, 47
– virus-induced 5
heart tissue antigens 264
hemagglutination inhibition 72
hepatitis 4, 59
herpangina 66
heterotypic response 15
HR1 215
HR2 215
human enteroviruses 3
hydrophobic pocket 193
hypercholesterolemic diet 82

I
icosahedral viruses 192
IDDM (see diabetes mellitus, viral-induced-insulin-dependent)
idiopathic dilated cardiomyopathy 262
IgM 22, 34, 37, 39, 40, 42, 43, 46
– assays 72
– in dilated cardiomyopathy 42, 43
– in myocarditis 37, 39, 40
– in pericarditis 45, 46
immune response 24
immunosuppression 288
immunosuppressive therapy 299
in situ hybridization 34, 35, 37, 44
– in dilated cardiomyopathy 44
– in myocarditis 37
in situ PCR 34, 35, 37, 38, 41, 44

– in dilated cardiomyopathy 44
– in myocarditis 37, 38, 41
infants
– acute CNS complications 62
– aseptic meningitis 61
– undifferentiated fever 61, 62
infections, treatment 25
inflammatory
– heart disease 228
– muscle disease 20
integrin 212
interference assays, virus attachment 211
interferon-γ 271, 286f.
interleukin
– IL1 271
– IL2 286
– IL4 286
internal ribosome entry site (IRES) 170
intrauterine transmission 57
ion binding sites 204
IRES (see internal ribosome entry site)
islet cell cytoplasmic (ICA) autoantigens 266

J
juvenile dermatomyositis 20
JVB Benschoten strain 99, 131

K
Keshan disease 83–85
– epidemiology 84
knob surface protection 138

L
LBM pools 71
loop destabilizing energies 173
low pH resistance 3
lymphocyte 293

M
malnutrition 82
marasmus 82
meningitis, aseptic 16, 59, 62–65
meningoencephalitis 59
– chronic 65
mice 261
molecular
– mimicry 268
– probes 70
multiple hairpin prediction 174
murine myocarditis 228
– and T cells 285–290
muscle disease, inflammatory 20
myocardial
– damage 84
– disease 270f.
myocarditis (see also heart disease) 59, 60, 81–94, 228, 260, 283
– acute viral 299
– chronic 265
– clinical diagnosis 272
– immunopathogenic 285
– murine 228
– – T cells 285–290
myopathies, chronic 19
myristate 196

N
neonatal CVB infections 17, 54–61
– age-related susceptibility 55
– clinical manifestations 58
– – hepatitis 59
– – meningoencephalitis 59
– – meningitis, aspeptic 59
– – myocarditis 59
– – – mortality 59
– – pneumonitis 60

– immune response 55
– incidence 54
– infection by postnatal transmission 54, 58
– infection by vertical transmission 54f., 57
– maternal infections 58
– nosokomial 58
– passively transferred maternal antibody 58
– prevention 60, 61
– symptom onset 57
– treatment 60
– – intravenous immune glubulin (IVIG) 60
neurologic abnormalities 63
neurovirulent 247, 248
neutralization 72
noncardiovirulent CVB3/0 genome 231
nonstructural proteins 98, 107–109, 111–113, 116
– coding regions 106–116
– VPg 98
5' nontranslated region (5' NTR) 98, 170, 229, 242, 246
nucleic acid probes 21
nucleolin 221
nucleotid binding (NTP-B) motif 109
nucleotid changes 88
nucleotide 234 231
nutritional
– antioxidants 81–94
– deficiencies 237

O

optimal folding 174
oxidative stress 88–91

P

P1 regions 126, 242
P2 regions 106, 107
P3 regions 106, 107, 116, 129
palmitate molecule 198
pancreatitis 4, 238, 239, 242
paralytic myelitis 65
PCR 21, 33–35, 37, 38, 40, 41, 44, 71, 116
– in dilated cardiomyopathy 44, 45
– in myocarditis 37, 38, 40, 41
PEG-catalase 89
peptides 290
persistent virus replication 261
phenotype, changed 88
phylogenetic
– analysis 173
– comparison 176
picornaviruses 192
– cellular receptors 211
placenta 56
pleurodynia 67
pneumonia 66
pneumonitis 60
pocket factor 193
poliovirus 107, 178–182, 246–248
– capsid region 248
– coding region 247
– comparative sequence analysis 181
– internal ribosome entry site 180
– neurovirulence 180
– 5' NTR 180, 181
– ribosomal landing pad 180
– RNA secondary structure 180
polymyositis 68
– adult 20
prednisone 288
pregnancy 55, 56
pro-inflammatory response 262
protein coding region 98
protein translation 231
protein-RNA interactions 187
pseudoknot 175, 177

R
RCA (see regulators of complement activation)
recombination 23
recursive programs 174
regulators of complement activation (RCA) 216
rhabdomyosarcoma cells, human 213
rheumatologic
– diseases 68
– symptoms 65
ribosomal landing pad (RLP) 170
RLP (see ribosomal landing pad)
RmcA 214
RmcB 215
RNA
– chemical structure 171
– fingerprints 162
– higher order structures 169–187
– – secondary interactions 170
– – secondary structure 172
– – – predictions 173
– – structure predictions 170
– – – computer predictions 170, 174, 176
– – tertiary interactions 170, 172, 177, 178
– structure-function relationships 187
– transcription 231
RNA-RNA hybridization assays 162
RP-α 213
RT-PCR 116

S
Sabin vaccine 246, 247
β-sandwich 192
SCID mice 295
SECIS element 91
selenium 85–87, 237
– dietary deficiency 89
– glutathione peroxidase 85
– immune response 85
– phenotype change 86
– supplementation 86
– virus titers 85
selenoprotein genes 91
serologic testing 72
serology 15
serotypes 37–39, 43
short consensus repeat (SCR) domains 218, 219
skeletal muscle diseases 67, 68
slot blot 34, 35, 43
– in dilated cardiomyopathy 43
– in myocarditis 40
spontaneous abortion 20
stillbirths 20
Structurelab 177
β-structures 128
subclincal infections 23
super-computer 176, 178
superoxide dismutase 89
supportive care 74
SVDV (see swine vesicular disease virus)
swine vesicular disease virus (SVDV) 153
– antigenically related to CVB5 155
– capsid structures 160
– human infections 154
– single common ancestor 163
– site 1 160
– site 2 160
– site 3 160

T
T cell epitopes of CVB 290f.
T cells 283–300
Th1 236
Th2 236
Theiler's murine encephalomyelitis virus 248
– capsid proteins 248
thermodynamic parameters 173

transfer experiments 295
treatment 25, 74
tumor necrosis factor-α 271

U
upper respiratory infections 66

V
vaccines 73, 228, 251
variable region 102
vesicular diseases of pigs 154
viral persistence 24
virus
– chimeric 229
– entry 222
– isolation 21, 33, 37–39, 43
– – in dilated cardiomyopathy 43
– – in myocarditis 37–39
virus-receptor interactions 219–221
vitamin E 87, 237
– dietary deficiency 89
VP1, Thr-129 242
VP4, Arg-16 242

W
Watson-Crick base-pairs 172